IP Library › Granted Patent US 12,540,318
Granted Patent B2
US 12,540,318 · App. 16/074,128 · Granted Feb 3, 2026

Nucleic acids encoding chimeric polypeptides for library screening

Inventors: David Casagolda Vallribera (Penzberg, DE); Frank Kroner (Munich, DE); Michael Schraeml (Penzberg, DE)
Assignee: Roche Diagnostics Operations, Inc.
C12N15/1037C12N15/1034C12N15/62C40B40/06C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,318
App. No.
16/074,128
Granted
Feb 3, 2026
Kind
B2
Abstract

The present disclosure is directed to a library of chimeric polypeptides comprising one or more fragments from the peptidyl-prolyl cis/trans isomerase or FKBP family displaying one or more polypeptides on one or more FKBP members and its use in methods for the screening and selection of constrained peptide surrogates exhibiting binding activity versus predetermined target molecules.

Claims (33)

1 . A composition comprising nucleic acid molecules encoding a population comprising more than five non-identical chimeric polypeptide species, wherein each nucleic acid molecule encodes a chimeric polypeptide species that comprises a polypeptide according to formula I

NH 2 —S 2 —X—S 1 —COOH  (formula I),

wherein

X is an amino acid sequence comprising a variable sequence, wherein X is inserted in place of the insert-in-flap-domain (IF-domain) of the polypeptide,

S2 comprises an amino acid sequence selected from the list consisting of amino acids 1-63 of SEQ ID NO:4, amino acids 1-63 of SEQ ID NO:5, amino acids 1-68 of SEQ ID NO:6, amino acids 1-82 of SEQ ID NO:8, amino acids 1-65 of SEQ ID NO:12, amino acids 1-85 of SEQ ID NO:13, amino acids 1-84 of SEQ ID NO:9, amino acids 1-100 of SEQ ID NO:10, amino acids 1-86 of SEQ ID NO:11, amino acids 1-9 of SEQ ID NO:14, amino acids 1-108 of SEQ ID NO:15, amino acids 1-63 of SEQ ID NO:16, amino acids 1-63 of SEQ ID NO:17, and amino acid sequences at least 50% identical to any of the aforesaid amino acid sequences,

S1 comprises an amino acid sequence selected from the list consisting of amino acids 65-90 of SEQ ID NO:4, amino acids 65-152 of SEQ ID NO:5, amino acids 127-152 of SEQ ID NO:6, amino acids 138-156 of SEQ ID NO:8, amino acids 67-93 of SEQ ID NO:12, amino acids 87-106 of SEQ ID NO:13, amino acids 97-108 of SEQ ID NO:9, amino acids 118-129 of SEQ ID NO:10, amino acids 88-99 of SEQ ID NO:11, amino acids 11-45 of SEQ ID NO:14, amino acids 110-128 of SEQ ID NO:15, amino acids 65-90 of SEQ ID NO:16, amino acids 65-128 of SEQ ID NO:17, and amino acid sequences at least 50% identical to any of the aforesaid amino acid sequences,

S1 and S2 are non-variable for said more than five non-identical chimeric polypeptide species, and

— between two amino acids denotes a peptide bond.

2 . The composition according to claim 1 , wherein X comprises an amino acid sequence of 5 to 500 residues.

3 . The composition according to claim 1 , wherein X comprises an amino acid sequence of 5 to 75 residues.

4 . The composition according to claim 1 , wherein X is composed according to formula II

U—O—Z  (formula II),

wherein

O is an amino acid sequence comprising a variable sequence,

U and Z are selected independently of each other, wherein either is present or absent and, if present, each of U and/or Z is a non-variable amino acid sequence comprising 1 to 10 residues, wherein both U and Z cannot be absent in the same formula IL, and

U, if present, is linked with a peptide bond to S 2 , and Z, if present, is linked with a peptide bond to S 1 .

5 . The composition according to claim 4 , wherein each of U and/or Z is an amino acid sequence of 1 to 5 residues.

6 . The composition according to claim 4 , wherein the amino acid sequence of O is composed of a subset of the naturally occurring amino acid residues.

7 . The composition according to claim 6 , wherein each residue of the amino acid sequence of O is independently selected from the list of amino acid residues consisting of Y, F, L, P, D, V, R, Q, S, I, E, G, W, A, H, T, N, K, and M.

8 . The composition according to claim 7 , wherein in the population of encoded chimeric polypeptide species the average relative frequency of occurrence of a particular amino acid residue in the amino acid sequence of O is 8.5% to 11.5% for Y, 8.5% to 11.5% for F, 8.5% to 11.5% for L, 5% to 8% for P, 4.5% to 7.5% for D, 4.5% to 7.5% for V, 4.5% to 7.5% for R, 4% to 7% for Q, 4% to 7% for S, 3.5% to 6.5% for I, 3% to 6% for E, 3% to 6% for G, 3% to 6% for W, 3% to 6% for A, 2.5% to 5.5% for H, 2% to 5% for T, 1% to 4% for N, 0.5% to 3.5% for K, and 0.5% to 2.5% for M.

9 . The composition according to claim 1 , wherein the chimeric polypeptide species comprises the sequence of SEQ ID NO:4 or SEQ ID NO:5.

10 . The composition according to claim 1 , wherein S 2 comprises an amino acid sequence selected from the list consisting of amino acids 1-63 of SEQ ID NO:4, amino acids 1-63 of SEQ ID NO:5, amino acids 1-68 of SEQ ID NO:6, amino acids 1-82 of SEQ ID NO:8, amino acids 1-65 of SEQ ID NO:12, amino acids 1-85 of SEQ ID NO:13, amino acids 1-84 of SEQ ID NO:9, amino acids 1-100 of SEQ ID NO:10, amino acids 1-86 of SEQ ID NO:11, amino acids 1-9 of SEQ ID NO:14, amino acids 1-108 of SEQ ID NO:15, amino acids 1-63 of SEQ ID NO:16, amino acids 1-63 of SEQ ID NO:17, and amino acid sequences at least 70% identical to any of the aforesaid amino acid sequences; and wherein S 1 comprises an amino acid sequence selected from the list consisting of amino acids 65-90 of SEQ ID NO:4, amino acids 65-152 of SEQ ID NO:5, amino acids 127-152 of SEQ ID NO:6, amino acids 138-156 of SEQ ID NO:8, amino acids 67-93 of SEQ ID NO:12, amino acids 87-106 of SEQ ID NO:13, amino acids 97-108 of SEQ ID NO:9, amino acids 118-129 of SEQ ID NO:10, amino acids 88-99 of SEQ ID NO:11, amino acids 11-45 of SEQ ID NO:14, amino acids 110-128 of SEQ ID NO:15, amino acids 65-90 of SEQ ID NO:16, amino acids 65-128 of SEQ ID NO:17, and amino acid sequences at least 70% identical to any of the aforesaid amino acid sequences.

11 . The composition according to claim 1 , wherein S 2 comprises an amino acid sequence selected from the list consisting of amino acids 1-63 of SEQ ID NO:4, amino acids 1-63 of SEQ ID NO:5, amino acids 1-68 of SEQ ID NO:6, amino acids 1-82 of SEQ ID NO:8, amino acids 1-65 of SEQ ID NO:12, amino acids 1-85 of SEQ ID NO:13, amino acids 1-84 of SEQ ID NO:9, amino acids 1-100 of SEQ ID NO:10, amino acids 1-86 of SEQ ID NO:11, amino acids 1-9 of SEQ ID NO:14, amino acids 1-108 of SEQ ID NO:15, amino acids 1-63 of SEQ ID NO:16, amino acids 1-63 of SEQ ID NO:17, and amino acid sequences at least 80% identical to any of the aforesaid amino acid sequences; and wherein S 1 comprises an amino acid sequence selected from the list consisting of amino acids 65-90 of SEQ ID NO:4, amino acids 65-152 of SEQ ID NO:5, amino acids 127-152 of SEQ ID NO:6, amino acids 138-156 of SEQ ID NO:8, amino acids 67-93 of SEQ ID NO:12, amino acids 87-106 of SEQ ID NO:13, amino acids 97-108 of SEQ ID NO:9, amino acids 118-129 of SEQ ID NO:10, amino acids 88-99 of SEQ ID NO:11, amino acids 11-45 of SEQ ID NO:14, amino acids 110-128 of SEQ ID NO:15, amino acids 65-90 of SEQ ID NO:16, amino acids 65-128 of SEQ ID NO:17, and amino acid sequences at least 80% identical to any of the aforesaid amino acid sequences.

12 . The composition according to claim 1 , wherein S 2 comprises an amino acid sequence selected from the list consisting of amino acids 1-63 of SEQ ID NO:4, amino acids 1-63 of SEQ ID NO:5, amino acids 1-68 of SEQ ID NO:6, amino acids 1-82 of SEQ ID NO:8, amino acids 1-65 of SEQ ID NO:12, amino acids 1-85 of SEQ ID NO:13, amino acids 1-84 of SEQ ID NO:9, amino acids 1-100 of SEQ ID NO:10, amino acids 1-86 of SEQ ID NO:11, amino acids 1-9 of SEQ ID NO:14, amino acids 1-108 of SEQ ID NO:15, amino acids 1-63 of SEQ ID NO:16, amino acids 1-63 of SEQ ID NO:17, and amino acid sequences at least 90% identical to any of the aforesaid amino acid sequences; and wherein S 1 comprises an amino acid sequence selected from the list consisting of amino acids 65-90 of SEQ ID NO:4, amino acids 65-152 of SEQ ID NO:5, amino acids 127-152 of SEQ ID NO:6, amino acids 138-156 of SEQ ID NO:8, amino acids 67-93 of SEQ ID NO:12, amino acids 87-106 of SEQ ID NO:13, amino acids 97-108 of SEQ ID NO:9, amino acids 118-129 of SEQ ID NO:10, amino acids 88-99 of SEQ ID NO:11, amino acids 11-45 of SEQ ID NO:14, amino acids 110-128 of SEQ ID NO:15, amino acids 65-90 of SEQ ID NO:16, amino acids 65-128 of SEQ ID NO:17, and amino acid sequences at least 90% identical to any of the aforesaid amino acid sequences.

13 . The composition according to claim 1 , wherein S2 is an amino acid sequence selected from the list consisting of amino acids 1-63 of SEQ ID NO:4, amino acids 1-63 of SEQ ID NO:5, amino acids 1-68 of SEQ ID NO:6, amino acids 1-82 of SEQ ID NO:8, amino acids 1-65 of SEQ ID NO:12, amino acids 1-85 of SEQ ID NO:13, amino acids 1-84 of SEQ ID NO:9, amino acids 1-100 of SEQ ID NO:10, amino acids 1-86 of SEQ ID NO:11, amino acids 1-9 of SEQ ID NO:14, amino acids 1-108 of SEQ ID NO:15, amino acids 1-63 of SEQ ID NO:16, amino acids 1-63 of SEQ ID NO:17, and amino acid sequences at least 95% identical to any of the aforesaid amino acid sequences; and wherein S1 is an amino acid sequence selected from the list consisting of amino acids 65-90 of SEQ ID NO:4, amino acids 65-152 of SEQ ID NO:5, amino acids 127-152 of SEQ ID NO:6, amino acids 138-156 of SEQ ID NO:8, amino acids 67-93 of SEQ ID NO:12, amino acids 87-106 of SEQ ID NO:13, amino acids 97-108 of SEQ ID NO:9, amino acids 118-129 of SEQ ID NO:10, amino acids 88-99 of SEQ ID NO:11, amino acids 11-45 of SEQ ID NO:14, amino acids 110-128 of SEQ ID NO:15, amino acids 65-90 of SEQ ID NO:16, amino acids 65-128 of SEQ ID NO:17, and amino acid sequences at least 95% identical to any of the aforesaid amino acid sequences.

14 . The composition according to claim 4 , wherein X is composed according to formula II

U—O—Z  (formula II),

wherein

O a variable sequence according to formula IV

5′-(Lib-Lib1)6-Lib-3′  (formula IV)

wherein Lib is a mixture of trinucleotides encoding amino acids wherein the average relative frequence of occurrence of a particular amino acid residue is 10% for F, 10% for I, 9% for L, 8% for Y, 8% for W, 5% for S, 5% for D, 5% for G, 5% for P, 5% for R, 5% for E, 4% for V, 4% for A, 4% for H, 3% for N, 3% for K, 3% for T, 3% for Q, and 1% for M; and

wherein Lib1 is a mixture of trinucleotides encoding amino acids wherein the average relative frequency of occurrence of a particular amino acid residue is 11% for Y, 11% for L, 10% for F, 6% for S, 6% for D, 6% for G, 6% for R, 6% for E, 5% for V, 5% for A, 5% for H, 5% for K, 5% for P, 4% for N, 4% for T, 4% for Q, and 1% for M.

15 . The composition according to claim 1 , wherein said IF-domain consists of amino c acids 69 to 126 of SEQ ID NO:6, 83 to 137 of SEQ ID NO:8, 85 to 96 of SEQ ID NO:9, or 101 to 117 of SEQ ID NO:10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: VALLRIBERA, DAVID CASAGOLDA; KRONER, FRANK; SCHRAEML, MICHAEL
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 050151/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 050158/0435 →
Continuity (1)
Related Publication 20190292535A1 · Sep 26, 2019
References Cited (53)
US 20030096352A1 · Scholz · 2003 [cited by examiner]
US 20030206891A1 · Clackson · 2003 [cited by examiner]
EP 1025218A1 · 2000 [cited by applicant]
EP 1516928A1 · 2005 [cited by applicant]
EP 1621555A1 · 2006 [cited by applicant]
WO 2003000878A2 · 2003 [cited by applicant]
WO WO2006072773A1 · 2006 [cited by examiner]
WO 2007077008A1 · 2007 [cited by applicant]
WO 2012150320A1 · 2012 [cited by applicant]
Knappe et al. “Insertion of a Chaperone Domain Converts FKBP12 into a Powerful Catalyst of Protein Folding” J. Mol. Biol., 368(5): 1458-1468, May 18, 2007 (Year: 2007). [cited by examiner]
Rostam et al. “Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease” Clinical and Experimental Pharmacology and Physiology (2015, First published: Nov. 5, 2014) 42(2), 11… [cited by examiner]
Maruyama et al. “Archaeal peptidyl prolyl cis-trans isomerases (PPlases) update 2004” Front Biosci. May 1, 2004;9:1680-720; doi: 10.2741/1361 (Year: 2004). [cited by examiner]
Furutani et al. “Biochemical and Genetic Characterization of an FK506-Sensitive Peptidyl Prolyl cis-trans Isomerase from a Thermophilic Archaeon, Methanococcus thermolithotrophicus” (1998) J. Bacteriol., vol. 180, No. 2… [cited by examiner]
Henne et al (Nature Biotechnology 22:547-53) (Year: 2004). [cited by examiner]
Abe et al., The changes in crosslink contents in tissues after formalin fixation; Analytical Biochemistry; vol. 318, 2003, pp. 118-123. [cited by applicant]
Binz et al., Engineering novel binding proteins from nonimmunoglobulin domains; Nat. Biotechnol, vol. 23, pp. 1257-1268, 2005. [cited by applicant]
Bird et al., Synthesis and Biophysical Characterization of Stabilized α-Helices of BCL-2 Domains; Methods in Enzymology, vol. 446, pp. 369-386, 2008. [cited by applicant]
Brecht et al., Changes in Peptidyl-Prolyl CIS/TRANS Isomerase Activity and FK506 Binding Protein Expression Following Neuroprotection by FK506 in the Ischemic Rat Brain; Neuroscience, vol. 120, 2003, pp. 1037-1048. [cited by applicant]
Decenzo et al., FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes; Protein Engineering, vol. 0, No. 2, 1996, pp. 173-180. [cited by applicant]
Gumbart et al., Mechanisms of SecM-Mediated Stalling in the Ribosome; Biophysical Journal, vol. 103, 2012, pp. 331-341. [cited by applicant]
Hoffmann et al., New Binding Mode to TNF-Alpha Revealed by Ubiquitin-Based Artificial Binding Protein; PloS one; 2012, vol. 7, No. 2, pp. e31298. [cited by applicant]
Hosse et al., A new generation of protein display scaffolds for molecular recognition; Protein Science, 2006, pp. 14-27. [cited by applicant]
Ideno et al., Expression of foreign proteins in [cited by applicant]
Knappe et al., Insertion of a Chaperone Domain Converts FKBP-12 into a Powerful Catalyst of Protein Folding; J. Mol. Biol, 2007, vol. 368, pp. 1458-1468. [cited by applicant]
Knappik et al., Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides; J. Mol. Biol., 2000, vol. 596, pp. 57-88. [cited by applicant]
Liu et al., Engineering a tRNA and aminoacyl-tRNA synthetase for the site-specific incorporation of unnatural amino acids into proteins in vivo; Proc. Natl. Acad. Sci., 1997, vol. 94, pp. 10095-10097. [cited by applicant]
London et al., The Structural Basis of Peptide-Protein Binding Strategies; Cell Press; Structure 18, pp. 188-199, (2010). [cited by applicant]
Low et al., Crystal Structure Determination and Functional Characterization of the Metallochaperone SlyD from Thermus thermophilus; J. Mol. Biol., 2010, vol. 398, pp. 375-390. [cited by applicant]
Mattheakis et al., An in vitro polysome display system for identifying ligands from very large peptide libraries; Proc. Natl. Acad., Sci., vol. 91, 1004, pp. 9022-9026. [cited by applicant]
Mcnamara et al., Peptides Constrained by an Aliphatic Linkage between Two Cα Sites: Design, Synthesis, and Unexpected Conformational Properties of an i,(i+4)-Linked Peptide; J. Org. Chem, 2001, vol. 66, pp. 4585-4594. [cited by applicant]
Nakatogawa et al., The Ribosomal Exit Tunnel Functions as a Discriminating Gate; Cell, vol. 1-08, 2002, pp. 629-636. [cited by applicant]
Pace et al., How to measure and predict the molar absorption coefficient of a protein; Protein Science, 1995, vol. 4, pp. 2411-2423. [cited by applicant]
Russo et al., Osmolyte Effects on Kinetics of FKBP12 C22A Folding Coupled with Prolyl Isomerization; 2003, J. Mol. Biol, vol. 330, pp. 851-866. [cited by applicant]
Scholz et al., Autocatalytic Folding of the Folding Catalyst FKBP12; The Journal of Biological Chemistry; 1996, vol. 271, No. 22, pp. 12703-12707. [cited by applicant]
Schories et al., Multimer Formation by FKBP-12: roles for cysteine 23 and phenylalanine 36; Journal of Peptide Science; 2007; vol. 13, pp. 475-480. [cited by applicant]
Skerra A., Corrigendum; Engineered protein scaffolds for molecular recognition; Journal of Molecular Recognition, 2000, vol. 13, pp. 167-187. [cited by applicant]
Standaert et al., Molecular cloning and overexpression of the human FK506-binding protein FKBP; Nature, 1990, vol. 346, pp. 671-674. [cited by applicant]
Steiner et al., Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display; 2008, J. Mol. Biol., vol. 382, pp. 1211-1227. [cited by applicant]
Suzuki et al., Three-dimensional Solution Structure of an Archaeal FKBP with a Dual Function of Peptidyl Prolyl cis-trans Isomerase and Chaperone-like Activities; J. Mol. Biol., 2003, vol. 328, pp. 1149-1160. [cited by applicant]
Timerman et al., Characterization of an Exchange Reaction between Soluble FKBP-12 and the FKBP Ryanodine Receptor Complex; The Journal of Biological Chemistry; vol. 270, No. 6, 1995, pp. 2451-2459. [cited by applicant]
Lipovsek et al., In-vitro protein evolution by ribosome display and mRNA display; Journal of Immunological Methods, 2004, vol. 290, pp. 51-67. [cited by applicant]
Kohler G., Milstein C., Continuous cultures of fused cells secretign antibody of predfined specificity; Nature; vol. 256, 1975, pp. 495-497. [cited by applicant]
International Search Report, European Patent Office, International Patent Application No. PCT/EP2012/072178, Jul. 12, 2013, 5 pages. [cited by applicant]
Written Opinion of the International Searching Authority, European Patent Office, International Patent Application No. PCT/EP2012/072178, Jul. 12, 2013, 4 pages. [cited by applicant]
International Preliminary Report on Patentability, European Patent Office, International Patent Application No. PCT/EP2012/072178, May 12, 2015, 5 pages. [cited by applicant]
Fields et al., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman & Co., 56 pages. [cited by applicant]
Skerra et al., Corrigendum, J. Mol. Recognit., vol. 13, 2000, p. 409. [cited by applicant]
Ueda et al., Ribosome Display with the PURE Technology, Methods Mol. Biol., vol. 607, 2010, pp. 219-225. [cited by applicant]
Rizo J.; Gierasch L.M., Constrained Peptides: Models of Bioactive Peptides and Protein Sustructures, Annu. Rev. Biochem., vol. 61, 1992, pp. 387-418. [cited by applicant]
Handschumacher, R.E. et al., Cyclophilbt:. A Specific Cytosolic Binding Protein for Cyclosporin A, Science, vol. 226, 1984, pp. 544-547. [cited by applicant]
Zemlin, M. et al., Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of Structures, J Mol Biol, vol. 334, 2003, pp. … [cited by applicant]
Zoldak, G. et al., Consequences of Domain Insertion on the Stability and Folding Mechanism of a Protein, J. Mol. Biol., vol. 386, 2009, pp. 1138-1152. [cited by applicant]
Schaegger, H.; Jagow, G., Tricine-Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis for the Separation of Proteins in the Range from 1 to 100 kDa, Anal. Biochem., vol. 166, 1987, pp. 368-379. [cited by applicant]